Brought to you by 
Pharmacia co-promotes Celltech's CDP870; terminated
Mar 2001
Executive Summary
Celltech has granted Pharmacia exclusive worldwide co-development and co-promotion rights to its autoimmune disease product CDP 870--in Phase IIb for mild to severe rheumatoid arthritis (RA) and Phase II for Crohn's disease--as well as all TNF-a (tumor necrocis factor alpha) inhibitor antibody-based products in development for RA by Celltech.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Co-Promotion
- R+D and Marketing-Licensing
- Product or Technology Swap
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pharmacia co-promotes Celltech's CDP870; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice